Aegerion announced the launched of three new dosage strengths for Juxtapid (lomitapide mesylate): 30mg, 40mg and 60mg strength capsules.

Juxtapid is approved as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol, apolipoprotein B and non- high-density-lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia (HoFH). It is a MTP-inhibitor that reduces blood cholesterol and triglyceride levels by limiting the production of lipoproteins from the intestine and liver.

RELATED: Dyslipidemia Drug Indications

Juxtapid capsules are now available in 5mg, 10mg, 20mg, 30mg, 40mg and 60mg strengths in 28-count bottles.

For more information call (855) 305-2347 or visit